Gene therapy injection tested to halt vision loss in rare eye disease
NCT ID NCT07063030
Summary
This early-stage study is testing a new gene therapy called LX107 for people with a rare inherited eye disease that causes vision loss. Doctors will inject the therapy directly into the retina of one eye in up to 13 patients to see if it is safe and if it can improve or stabilize vision. The main goal is to check for side effects, while also measuring changes in vision, light sensitivity, and mobility over a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINAL DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.